Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …

In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for
prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have …

Atrial fibrillation (AF) is the most commonly observed rhythm disorder in clinical practice. It is
associated with a high risk of thromboembolic stroke and increased cardiovascular mortality …

Purpose The nonvitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban,
apixaban, and edoxaban are used for the reduction of the risk of stroke or systemic …

Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more
than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial …

Atrial fibrillation (AF) increases a patient's stroke risk four-to five-fold. Anticoagulation with
the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin …

The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …

Atrial fibrillation (AF) confers an increased risk of ischemic stroke or thromboembolism that is
reduced by long‐term oral anticoagulant therapy. Until recently, the latter has typically been …

Patients with nonvalvular atrial fibrillation (AF) and risk factors for stroke need
anticoagulation to avoid thromboembolic complications. Vitamin K antagonists (VKAs) are …

Atrial fibrillation (AF) is a major cause of ischaemic stroke. The majority of these strokes can
be prevented by treatment with oral anticoagulation therapy. The advent of non-vitamin K …